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Sumnisry 
The outcome of immune responses critically  depends on the pattern of lymphokines secreted 
by CD4 + T  cells. CD4 + T  cells may differentiate into interleuldn 2 (IL-2) and interferon 3' 
secreting T helper 1 (Thl)-like cells or IL-4/IL-5/IL-IO  secreting Th2-1ike cells. However, the 
mechanisms that regulate production of IL-4 or other T cell lymphokines in vivo remain unknown. 
We use the superantigen, Staphylococcus enterotoxin A (SEA), as a model antigen to characterize 
the signals that regulate the production of IL-4 in vivo. Induction of IL-4 in normal CD4 + 
T cells required stimulation with both antigen and IL-4. SEA-specific CD4 + T cells produced 
large amounts of IL-4 when restimulated within 10 d after in vivo priming. Repetitive application 
of both signals was required to prevent downregulation of IL-4 production. Although controversy 
exists regarding the susceptibility of Th2-1ike cells to tolerogenic signals, high doses of superantigen 
readily abolished the capacity to produce IL-4 in both naive T cells and in T cells already primed 
for IL-4 production. Infection with the nematode, Nippostrong,flus brasiliensis, reversed the established 
T cell tolerance, whereas the signals which induced IL-4 production in normal T cells, antigen 
and IL-4, were not capable of reversing superantigen-specific tolerance in vivo. The major parameter 
that correlated with the capacity of parasitic  infection to break tolerance was the magnitude 
of the lymphoproliferation seen during the course of the infection. The capacity to activate or 
tolerize the IL-4 pathway in an antigen-specific fashion should prove useful in the design of antigen- 
specific therapies for autoimmune and allergic diseases. 
2•ctivation 
of CD4 + T  cells by their target antigens and 
APC induces a cascade of differentiation events that re- 
sult primarily in the secretion of IL-2. During the subsequent 
course of the immune response, CD4 + T cells may differen- 
tiate into IL-2 and IFN-3, secreting Thl-like cells or IL-4/IL- 
5/IL-10 secreting Th-2 like calls (1, 2). Thus, T call activa- 
tion by antigen and APC initiates not only effector T  cell 
functions, but also programs the lymphokine pattern that 
primed T cells secrete during subsequent interactions with 
thdr target antigens. Although a number of factors have been 
proposed (3-13) to regnlate the type of lymphokine  produced, 
it appears that lymphokines themselves may play the most 
dominant role in the regulation of the capacity of naive T 
cells to differentiate into Thl- or Th2-like populations (9-12). 
The requirements for the induction of the IL-4 pathway 
have been extensively characterized  in vitro (8-12).  The ca- 
pacity to produce IL-4 is not a predetermined characteristic 
of a subpopulation of CD4 + T calls, but reflects a differen- 
tiation event during the process of T cell activation (2). The 
presence of IL-4 at the time of stimulation of T cells with 
either polyclonal activators or specific antigen results in the 
priming of T cell populations which, when restimulated, pro- 
duce high levels of IL-4, but little or no IL-2 or IFN-3,. Con- 
versely, activation of resting T  cells in the absence of IL-4 
results in the priming for IFN-3, production and this priming 
can be blocked by the presence of IL-4. Although IL-4 can 
readily be induced in vivo with polyclonal stimulators (8-12) 
such as injection of anti-IgD or parasite infection, the specific 
signals needed to induce IL-4 could not be readily analyzed. 
Induction of IL-4 can be diminished by treatment of animals 
with anti-IL-4, suggesting that IL-4 is also required for its 
own induction in vivo (4,  14-17). 
Although progress has been made in understanding the 
regulation of the induction of cytokine production, much 
less is known and considerable controversy exists regarding 
the requirements for  the  induction of nonresponsiveness 
or anergy in Thl- and Th2-1ike CD4 + T cells. CD4 + Thl 
clones can be easily rendered anergic by culture with antigen- 
pulsed, fixed APC or plate-bound anti-CD3, whereas similar 
treatment of Th2 clones results in no diminution of their 
capacity to produce IL-4 (18-23).  It is difficult to generalize 
from these studies of T  cell clones  as to the requirements 
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the protocols developed  for use with clones are  rdatively 
ineffective in the induction of anergy in naive or short-term 
stimulated T calls. Studies in vivo have similarly  demonstrated 
that those strategies  that permit the induction of tolerance, 
such as the injection of deaggregated human IgG or high 
doses of hapten-protein conjugates, result in a selective de- 
ficiency of antigen-specific  proliferation, IL-2,  and IFN-3, 
production, but prime rather than tolerize IL-4-producing 
cells (24-26). Taken together, these as weU as other studies 
(27-29) strongly suggest that the IL-4 pathway is profound- 
ly resistant to tolerance induction both in vitro and in vivo, 
or  alternatively, that  the conditions for the induction of 
tolerance in Th2-1ike cells have not yet been defined. 
Here we use the superantigen, Staphylococcus enterotoxin 
A (SEA), 1 as a model antigen to characterize the signals that 
regulate the IL-4 pathway in vivo. In BALB/c mice, SEA selec- 
tively activates TCR V31 + and V310 + T cells (30), without 
detectable priming for IL-4. First, we demonstrated that ad- 
ministration of IL-4 during the period of T  ceU activation 
with SEA was required to prime T  cells in vivo for IL-4 
production. We then tested the responsiveness  of the IL-4 
pathway to tolerogenic signals in vivo. It is surprising that 
the IL-4 pathways of  both naive and primed T cells were highly 
susceptible  to tolerance induction. Lastly, the restoration of 
the IL-4 pathway in tolerant T cells required polyclonal acti- 
vation and expansion of  the tolerant population, whereas those 
stimuli which were effective in priming naive T cells for IL-4 
production failed to induce IL-4 in tolerant T  cells. 
Materials and Methods 
Animals.  Vires-free female  BALB/c  mice were purchased from 
Frederick Animal Facility (National Cancer Institute, National In- 
stitutes of Health [NIH], Frederick, MD) and maintained in the 
animal facility of the Laboratory of Immunology, National Insti- 
tutes of Allergy and Infectious Diseases [LI, NIAID],  NIH. All 
mice were used between 6 and 15 wk of age and were cared for 
according to NIH guidelines. 
Antibodies, Cytokines, and Supemntigens.  PE-hbeled anti-mouse 
CD4 mAb, GK 1.5, was purchased from Becton Dickinson & Co. 
(Mountain View, CA); FITCqabcled  anti-TCR VBI0 and anti-TCR 
VO6 mAb were purchased from PharMingen (San Diego, CA); 
and purified rat anti-mouse IL-4 mAb 111311 prepared by Verax 
Corp. (Hanover, NH) was a generous gift from Dr. W. E. Paul 
(LI, NIAID, NIH). Rat anti-mouse Fcg mAb (24G2; American 
Type Culture  Collection [ATCC], Rockville, ME)) was used as 
diluted ascites. Highly purified, murine rlL-4 was the generous gift 
of Dr. A. Levine (Monsanto Corp., St. Louis, MO). 1 #g of Ib4 
had the biological activity of 2 x  103 U. Human rlL-2 was a gift 
from Cetus Corp. (Emeryville,  CA). SEA was purchased  from Toxin 
Technologies (Sarasota, FL) and SEB from Sigma Chemical Co. 
(St. Louis,  MO). For cell  separations, we used anti-CD8 mAb 3.155, 
anti-CD4 mAb RL172, and anti-Thy 1.2 mAb HO 13.4 as hy- 
bridoma supernatants (ATCC). 
In Vivo Treatment.  Mice  were primed by a single subcutaneous 
injection of 50/~g SEA. Immediately after the first injection and 
1Abbreviation used in this paper: SEA, Staphylococcus  enterotoxin A. 
subsequently every  8 h, the mice received  the indicated dose of IL-4 
intraperitoneally. SEA-specific tolerance was induced by a single 
subcutaneous injection of 100/zg SEA. In selected experiments, 
animals were infected subcutaneously at the indicated time with 
700 third stage  larvae ofN. bras/l/ens/s  as previously  descnl~l (14, 29). 
Pnpatau'on ofTCells and Accessory (?,elk  Mesenteric  lymph nodes 
and spleens  were isolated and depleted of erythrocytes  by lysis  with 
ACK buffer. The cells  were then incubated  with anti-CDS, washed, 
and CD4+-enriched cells isolated by passage over mouse T cell 
columus (Biotex, Edmonton, Alberta, Canada). The resultant prepa- 
rations were highly enriched in CD4 + cells and contained no de- 
tectable CD8 § cells. Accessory  cells were prepared from the spleen 
of untreated, syngenic mice. After lysis with ACK lysing buffer, 
the cells  were incubated with anti-CD8, anti-CD4 mAb, and anti- 
Thy 1.2, washed, and subsequently incubated for 45 min at 37~ 
with rabbit C (Cedarhne, Westbttry,  NY). These preparations con- 
tained no detectable CD4 + or CD8 + ceils. Before use, accessory 
cells were irradiated with 3,000 rad from a Cesium source. 
In Vitro Stimulation.  CD4+-enriched cells were seeded in 96- 
well plates at three different cell numbers (0.25, 0.5, and 106 cells) 
together with 103 accessory cells in 250 #1 of DMEM medium 
supplemented  with 10% heat inactivated  FCS (Biofluids,  Inc., Rock- 
ville, ME)), t-glutamine (2 mM), 2 B-ME (0.05 mM), sodium pyru- 
vate (1 mM), penicillin  (100 U/ml), and streptomycin (100/~g/ml). 
Cells from each  ~perimental group were cultured with media  alone, 
with SEA (10/zg/ml),  or with SEB (10/~g/ml) in the presence 
of rIL-2 (5 U/ml). After 2 d, supernatants were immediately used 
for lymphokine analysis or stored at  -20~ 
Lyraphokine Analysis.  The II.,2 and Ib4 content of the culture 
supematants was determined  by assay  on the IL-2-dependent  CTLL 
cell line and on the IL-4-dependent CT.4S cell line (31), respec- 
tively. Serial dilutions of 2-d culture supernatants were incubated 
with CTLL (5  x  103) in the presence of anti-IL-4  mAb 111311 (32) 
or with CT.4S cells (5  x  103). All assays also contained controls 
in which the cell lines were incubated with known amounts of 
ri1r  and rib4. [3H]TdIL  incorporation was assayed after 20 h of 
culture (CTLL) or after 44 h of culture (CT.4S). 1 U of I1.-2 was 
defined  as half-maximal  stimulation of CTLL cells; we could regu- 
larly detect 0.01 U/ml of IL-2. Lymphokine production is shown 
as units of IL-2 or Ib4 produced at a cell density of 10  ~ cells/m1. 
FACS  ~ Analysis.  For FACS  |  analysis  (Becton  Dickinson & Co.) 
freshly prepared lymph node or spleen cells (10  e) were first in- 
cubated with mAb 24G2 and subsequently  stained  for 30 min with 
1-3/~g/ml of  directly  labeled anti-CD4 and anti-TCR VB10 or anti- 
CD4 and anti-TCR. V/36 at 4~  The cells were washed and the 
relative number of each cell population was determined by two 
color flowcytometry  using a FACScan  |  (Becton  Dickinson & Co.). 
Results 
Induction of  Antigen-specific  IL-4 Production In Viv~  Based 
on in vitro studies which demonstrate that induction of IL-4 
production in CD4 + T  cells requires both a TCR-mediated 
stimulus and IL-4, we speculated that the combined adminis- 
tration of nontolerogenic doses of SEA and IL-4 should up- 
regulate the IL-4 pathway in vivo. Animals were primed with 
a single injection of SEA (50/xg) and treated on days 0-2 
with IL-4 (1/~g every 8 h). Control animals received SEA 
alone, IL-4 alone, or no treatment. On day 6 after priming, 
CD4 + T  calls were isolated from both lymph nodes and 
spleen and evaluated for lymphokine production in vitro after 
stimulation with either SEA or SEB. CD4 + T  cells from 
1886  Regulation  of the IL-4 Pathway In Vivo untreated animals or animals treated with SEA alone or IL-4 
alone produced no detectable IL-4 when stimulated in vitro 
(Fig.  1, A  and B). In sharp contrast, CD4 + T cells isolated 
from animals primed with SEA and IL-4 produced large 
amounts of IL-4 when restimulated in vitro with SEA.  In 
10 independent studies, IL-4 production was upregulated be- 
tween 100- and 1,000-fold.  IL-4 was induced sdectively in 
SEA-responsive T calls since SEB-responsive T ceils from the 
same animals produced no detectable IL-4 when challenged 
in vitro (Fig. 1, A and B). Induction of IL-4 production was 
not observed at doses of IL-4 <1/zg every 8 h  (Fig.  1 B). 
The absolute amount of IL-4 produced by SEA-responsive 
CD4 + T  cells by this priming protocol varied in different 
experiments by a factor of 10. To compare the efficiency of 
priming for IL-4 production by injection of SEA and IL-4 
with a well-characterized stimulus for the induction of IL-4 
in vivo, we compared the IL-4-producing capacity of T cells 
primed with SEA and IL-4 with the IL-4 producing capacity 
of  SEA-responsive T calls derived from N. brasiliensis-infected 
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Figure  1.  Induction  of SEA-specific  Ib4 production  in CD4 + T cells. 
BALB/c mice were primed with a single subcutaneous  injection  of SEA 
(50 pg), with SEA and IL-4, with Ib4 alone, or received no treatment. 
Immediately  with the first injection  of SEA and subsequently  every  8 h, 
the mice  received  nine  injections  oflb4 (1 pg every  8 h, i.p., [A] or 0.1-2 
~g [B]). CD4 + lymph  node and spleen cens were isohted on day 6 after 
priming with SEA and IL-4  production  was measured after stimulation 
with syngeneic  APC and either SEA (10 ~g/ml) or SEB (10 pg/ml) in 
the presence of rIL-2 (5 U/ml). (.4) 1 of 10 similar experiments. 
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Figure  2.  CD4 § T cells from animals primed with SEA and II.-4 or 
from animals  infected  with N. brasiliensis  produce equivalent  amounts  of 
IL-4. BALB/c  mice  were infected  with 700 third  stage  larwae  ofN. bats///em/s, 
primed with SEA and Ib4 (1 ~tg every  8 h for 3 d), or received no treat- 
ment. II,4 production by CD4 +-enriched lymph node and spleen cells 
was assayed  on day 8 after  infection  or priming with SEA and Ib4 as de- 
scribed in Fig. 1. 
animals.  N.  brasiliensis is one of the most powerful in vivo 
stimuli for induction of IL-4 production in CD4 § T  cells. 
Repeated  studies  demonstrated that  CD4 +  T  cells  from 
animals primed with SEA and IL-4 and animals infected with 
N. brasiliensis produced a very similar quantity of IL-4 in re- 
sponse to SEA in vitro (Fig.  2). 
Previous studies have shown that the induction of IL-4 
production in vitro or in vivo requires 3-6 d of stimulation. 
After priming with SEA and IL-4, SEA-specific IL-4-produc- 
ing CD4 + T  cells were first detectable after 3 d  and peak 
levels of IL-4 production were observed between days 6 and 
10 (Fig. 3 A). In most experiments, the capacity to produce 
IL-4 declined sharply between days 10 and 14. This sharp 
decline in CD4 +, SEA-responsive,  IL-4-producing T  ceils 
could either be due to a downregulation of the IL-4 pathway 
or  could be  secondary to  a  ddetion of the  CD4 +,  SEA 
responsive  (V~10)  population. However, as shown in Table 
1, the sharp decline in SEA-specific IL-4-producing T cells 
was  never  associated  with  a  detectable  decrease  in 
CD4+VB10 + T  cells. These kinetic studies suggested that 
the capacity of SEA and IL-4 to induce IL-4-producing T 
calls is only transient, and that the continuous presence  of 
the  inducing stimuli is  required  for  maintenance of the 
pathway. To directly test this possibility, we injected animals 
a second time with the stimuli originally required to activate 
the  IL-4  pathway in  CD4 +  T  cells.  Repriming  of the 
animals with SEA and IL-4 prevented downregulation of the 
IL-4 pathway (Fig.  3 B). 
Effect of Induction  of SEA-specific IL-4 Production on SEA- 
specific IL-2 Production.  Induction of IL-4-producing T cells 
in vitro and in certain situations in vivo has been associated 
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Figure 3.  Repetitive treatment with SEA and Ib4 pwcents downregu- 
lation of Ib4 production. (.4) BALB/c mice were either primed with a 
single subcutaneous injection of 50 ~tg SEA and 11"4 (1/~g every 8 h for 
3 d) or received  no treatment. CD4 + T cells were assayed for 11"4 produc- 
tion in response to SEA on the day indicated as described in the legend 
with a downregnlation of IL-2 production (2-4, 8,  11). To 
determine whether the priming regimen of superantigen and 
IL-4 activated IL-4 production independently of suppression 
of  the  IL-2  pathway,  we  measured  IL-2  production  by 
CD4 §  T  cells  from  animals  primed  with  SEA  alone  or 
primed with SEA and IL-4.  Injection of mice with 50/~g 
of SEA alone resulted in a 10-fold reduction of IL-2 produc- 
tion in response to SEA. A decline of similar magnitude was 
seen in the production of IFN-3, and IL-3 (data not shown). 
However, SEA-specific IL-2 production was  still  10 times 
higher than background,  and injection of animals with the 
combination of SEA and IL-4 did not further diminish the 
capacity to produce IL-2 (Fig. 4).  The two concentrations 
of IL-4 used in this study resulted in an increase of II.-4 produc- 
tion of two  to three orders of magnitude  (Fig.  1 B). 
Tolerization of the IL-4 Pathuny.  The ability to generate 
a potent SEA-specific IL-4 response in vivo allowed us  to 
directly investigate whether superantigen-induced tolerance 
only affects the IL-2 pathway or whether superantigens also 
tolerize the II,-4 pathway. We first injected BALB/c mice with 
a tolerogenic dose of SEA (100/~g) and 5 d later treated the 
animals with the priming regimen of SEA and IL-4. Pretreat- 
ment of mice with tolerogenic doses of SEA completely abol- 
ished their response to a subsequent treatment with SEA and 
IL-4 (Fig. 5 A). To determine if the IL-4 pathway is also sen- 
sitive to tolerizing signals applied during the induction phase, 
mice were primed with SEA (50/~g) and IL-4, but then re- 
ceived two additional injections of SEA (50/~g)  on days 3 
and  6.  When  CD4 +  T  cells from  these animals  were re- 
stimulated in vitro, they produced no detectable IL-4 in re- 
sponse to SEA (Fig. 5 B). This downregnlation of the IL-4 
to Fig. 1. (B) BALB/c  mice were primed with SEA and 11.,4 as in A or 
received no treatment. One group of the animals that had been primed 
with SEA and II.-4 received a second treatment with SEA (50/zg) and 
II,4 (1/~g every 8 h for 3 d), starting on day 7. On day 13, CD4 + cells 
were isolated and assayed for SEA-specific  IL4 production. 
Table  1.  Silencing of the IL-4 Pathway Is Not Associated with a Decrease in CD4 + V~IO + T  Cells 
In vivo treatment  Vfll0§  + cells 
Day 0  Day 3  Day 6  Lymph nodes  Spleen 
% 
None  None  None  7.9  6.4 
SEA  +  IL-4  None  None  5.8  5.3 
SEA  +  IL-4  None  SEA  4.5  5.1 
SEA  +  IL-4  SEA  SEA  6.8  7.0 
Animals received either no treatment or were primed with SEA (50 #g) and IL-4 (1 #g every 8 h for 3 d). Some of the animals received one or 
two additional injections of SEA (50 #g) on the indicated days. On day 12, lymph node and spleen cells were isolated and stained with anti-CD4 
and anti-Vfll0 mAb. The relative numbers of CD4+ Vfll0 + T cells were determined by FACS analysis. The data, derived from the experiments 
in Fig. 5, are representative of two to three independent experiments. 
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Figure 4.  Effect  of induction of II.-4 in CD4 + T cells on their capacity 
to produce IL-2. BALB/c mice were primed with a single subcutaneous 
injection of SEA (50 pg), with SEA and IL-4 (2.5 or 1 ~g every 8 h for 
3 d), or received no treatment. SEA-specific  Ib2 production by CD4 + 
cells was assayed on day 6 after priming. The results are representative 
of 10 similar experiments. 
pathway was not prevented by additional treatment with 
IL-4 (until day 6; data not shown). The downregnlation of 
IL-4 production was also not secondary to deletion of SEA- 
responsive CD4 + T  cells,  since animals that received one 
single or repetitive injections of SEA had similar percentages 
of SEA-responsive CD4 +  V~10 + T  cells in lymph nodes or 
spleen between days 6 and 12 after injection of SEA (Table 
1 and data not shown). 
As the ability of Th2 or Th0 T cell clones to produce IL-4 
is resistant to tolerogenic signals in vitro (20, 22, 23), it was 
of interest to examine in vivo the susceptibility of CD4 + T 
cells that had been primed for IL-4 production to tolerogenic 
signals. Mice were therefore primed with SEA and IL-4 and 
on day 6 after treatment, when IL-4 induction is maximal 
(Fig. 3 A), mice received a second injection of SEA (50 ~g). 
It is surprising that CD4 + T  cells from mice that received 
a second injection of SEA on day 6 produced <1%  of the 
IL-4 produced by T  cells  from control animals that were 
primed in identical fashion, but that did not receive the second 
injection of SEA (Fig.  5  C). 
Reactivation of the IL.4 Pathway.  The failure to induce IL-4 
in SEA-tolerant CD4 + T  cells by treatment with SEA and 
IL-4 appears to conflict with our previous study which showed 
that N. brasiliensis infection induced SEB-specific IL-4 produc- 
tion in SEB-tolerant CD4 + T  calls (29). 
To study more closely the requirements to induce IL-4 in 
tolerant CD4 + T  cells,  CD4 + T  cells from SEA-tolerant 
and control mice were isolated at different times after infec- 
tion with N. brasiliensis. On day 7 after infection, CD4 + T 
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Figure 5.  The IL-4  pathway is susceptible  to tolerance induction  in both 
naive T cells and T cells primed for Ib4 production. (A) Induction of 
tolerance in naive T cells. Animals were not treated or primed with SEA 
(100 ~g, group Ill). On day 6, animals in groups II and III were injected 
with SEA (50 ~g) and IL-4 (1 ~g every 8 h for 3 d). On day 12, CD4 + 
T cells were isolated and assayed for SEA-spedfic II,4 production. (B) In- 
duction of tolerance during priming for II.,4 production. Animals were 
not treated or primed with SEA (50 ~g) and IL,4 (1/~g every 8 h for 
3 d). Animals in group III received two additional injections of SEA (50 
~g) on days 3 and 6. On day 12, CD4 + T cells were isolated and assayed 
for SEA-specific  II.,4 production. (C) Induction  of T cell tolerance in primed 
T cells. Animals were not treated or primed with SEA (50 ~g) and Ib4 
(1 ~g every 8 h for 3 d).  Animals in group III received one additional 
injection of SEA (50 ~g) on day 6. On day 12, CD4 + cells were isolated 
and assayed for SEA-specific  Ib4 production.  The percentage of V~10 + 
cells among CD4 + T calls is shown in Table 1. Similar results were ob- 
tained in two to three other experiments. IN VlVO TREATMENT 
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Figure  6.  Reactivation of the tolerant II~4 pathway requi~s reprogram- 
ming during parasite-mediated cell division. Mice were either primed with 
SEA (100/~g) or received no treatment. On day 6, animals were treated 
with SEA (50/~g) and IL-4 (1/~g every 8 h for 3 d), with SEA (50/~g) 
and infection with N. brasiliensis, or only infected with N. brasiliensis. On 
day 13 (A) or on day 15 (B), the number of mesenteric lymph node cells 
was determined,  and CD4 + T cells were assayed for IL-4 production in 
response to SEA or SEB. 
cells from SEA-tolerant mice were not capable of producing 
IL-4 in response to SEA, whereas IL-4 was readily detected 
in SEB-responsive control populations (Fig. 6 A). However, 
on day 9 after infection, CD4 + T  cells from SEA-tolerant 
mice produced large amounts of IL-4 when challenged with 
SEA (Fig. 6 B). Although the absolute amount of IL-4 pro- 
duced by CD4 + cells from tolerant animals was still about 
fivefold lower than the amount of IL-4 produced by CD4 + 
cells from control animals, IV. brasiliensis infection induced 
more than a 100-fold increase in SEA-specific IL-4 produc- 
tion in the tolerant animals (Fig.  6 B).  There was a close 
correlation between the magnitude of parasite-induced lym- 
phoproliferation and the reversion of SEA-specific tolerance. 
At day 7 after the infection, the number of lymph node cells 
was only moderately increased, whereas the number of lymph 
node cells increased 3.5-fold during the next 2 d of infection 
(Fig. 6, A and B). However, the percentage of CD4+VB10 + 
T cells was constant (data not shown) during the entire period 
of infection with N. brasiliensis, indicating in vivo expansion 
Discussion 
Previous  studies in vitro have strongly implied that one 
of the most critical factors that determines the differentia- 
tion of resting T cells into Th2-1ike IL-4--producing cells is 
IL-4 itself (8-12).  We have analyzed  the immune response 
to the superantigen, SEA, to determine the requirements for 
the induction of a Th2-like response in vivo.  Priming of 
animals with SEA together with IL-4 resulted in a marked 
upregulation of SEA-specific Th2-like ceils. Administration 
of either antigen alone or IL-4 alone failed to prime for IL-4 
production. The induction of IL-4 was completely specific 
for the superantigen injected as no IL-4 production was seen 
in response to the control superantigen, SEB. When mice 
were injected with IL-4 for 3 d after priming with SEA, our 
ability to detect IL-4-producing T cells in vitro persisted until 
days 10-12, but not longer. It is unlikely that the waning 
of the IL-4-producing population was secondary to deletion 
of the superantigen-specific T cells, as no deletion of the SEA- 
responsive V~ populations was observed. Continued adminis- 
tration of IL-4 and SEA was required to maintain the Th2- 
like cells in vivo. 
The requirement of IL-4 for the priming of Th2 cells in 
vivo is quite consistent with the results of studies that have 
used polydonal inducers of IL-4 production and anti-IL-4 
mAbs to define the role of IL-4 in priming for Th2-like re- 
sponses (15, 17, 33). However, very few studies have attempted 
to characterize in vivo the signals required for the induction 
of IL-4 in normal CD4 § T cells. Chatelain et al. (34) have 
shown that injection of healer C3H mice with IL-4 locally 
into  Leishraania-infected  footpads results  in  an  increased 
production of IL-4 and IL-5, but a decreased production of 
IFN-3', by draining lymph node cells harvested 48 h later. 
However,  this shift in cytokine production was only tran- 
sient, and all animals were ultimately able to heal their infec- 
tions and produced Thl-like responses upon in vitro challenge. 
Although our studies define the minimal requirements for 
the induction of IL-4 in normal T cells, it should be empha- 
sized that it is very difficult to rule out the involvement of 
other cytokines particularly, IL-2,  in the differentiation of 
SEA-specific  Th2-like cells in vivo. A number of in vitro studies 
have suggested that IL-2 is required both for the induction 
and production of IL-4 (10, 12, 29, 35). The concentration 
of SEA we used for the induction of IL-4 was only partially 
tolerogenic, and SEA-responsive T cells were still capable of 
producing measurable amounts of IL-2 when stimulated in 
vitro with SEA. Thus, sufficient IL-2 may have been gener- 
ated after injection of SEA and IL-4 to facilitate induction 
of IL-4 in CD4 + T  cells. Alternatively, it is possible that 
in vivo, other cytokines can substitute for IL-2, as recently 
suggested by studies with mice with targeted disruption of 
the IL-2 gene (36). In preliminary experiments, we have ob- 
served that treatment of mice with anti-IL-2 or with cy- 
closporin A at the time of priming with SEA and IL-4 did 
of the SEA-responsive T cells. As previously reported (29), 
induction of IL-4 production was not accompanied by de- 
tectable  SEA-specific IL-2 production (data not shown). 
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T  cells. 
Our ability to specifically prime superantigen-specific  IL- 
4-producing T cells in vivo allowed us to directly examine 
if IL-4-producing T cells could be tolerized in vivo. When 
SEA was first administered in a tolerogenic dose, our ability 
to prime for IL-4-producing T cells with SEA and IL-4 was 
completely abrogated. It is surprising that tolerance could 
also be induced in primed IL-4-producing cells. This dra- 
matic susceptibility of Th2-1ike cells to tolerance induction 
is at marked variance with studies on Th2 and Th0 T  cell 
clones in vitro in which the production of IL-4 is resistant 
to tolerogenic signals (22). It should be emphasized that our 
studies do not allow any conclusions to be drawn about the 
mechanism of induction of Th2-1ike T cell tolerance. As noted 
above, induction and expansion of Th2-1ike T  cells in vivo 
may require IL-2, and the tolerization protocols used in our 
studies may tolerize the IL-2 pathway and thus inhibit the 
development or continued expansion of Th2-1ike T cells. IL-4 
production by Th2 or Th0 clones in vitro may be indepen- 
dent of IL-2  and therefore resistant  to  the  induction of 
tolerance. 
Considerable controversy exists as to whether tolerogenic 
signals can silence the IL-4 pathway in vivo. Some studies 
have demonstrated that injection of mice with high concen- 
trations of antigen, which results in suppression of IL-2 and 
IFN-'y  production,  primes for  IL-4  production (24-26), 
whereas other studies have shown that similar treatment in- 
hibits the development of IL-4-producing cells and decreases 
antibody production after administration of the peptide an- 
tigen in adjuvant (37, 38).  Our data strongly suggest that 
induction or inhibition of IL-4 production critically depends 
on the dose of antigen as well as the amount of IL-4 supplied 
during T cell stimulation. One single injection of SEA (50 
#g) together with IL-4 primed T cells for optimal IL-4 produc- 
tion, whereas two additional injection of SEA (50 #g) com- 
pletely inhibited the development of IL-4-producing T cells. 
Similarly,  CD4 +  T  cells  that  had been primed for  IL-4 
production could be readily tolerized by reinjection of SEA, 
but this SEA-induced downregulation could be prevented by 
the simultaneous administration of IL-4. The susceptibility 
of primed Th2-1ike cells to tolerance induction in vivo has 
important implications for the design of therapeutic strate- 
gies for the immunomodulation of allergic diseases. 
Our ability to reprodudbly tolerize Th2-1ike cells afforded 
us the opportunity to reexamine the requirement for breaking 
T  cell tolerance in vivo.  We have previously shown that 
N. brasiliensis infection of animals tolerized with SEB resulted 
in a normal expansion of SEB-specific CD4+VB8 + T ceils 
in vivo as well as an equivalent increase of SEB-reactive IL- 
4-producing T cells (29). We interpreted these studies as in- 
dicating that SEB injection rendered the IL-4-producing T 
cell population tolerant and that infection with N. brasiliensis 
resulted in breaking of the tolerant state by the induction 
of IL-4 in SEB-tolerant T calls. However, since we could not 
directly demonstrate that we had tolerized the IL-4 pathway 
in SEB-responsive calls, we could not exclude the possibility 
that infection with N. brasiliensis resulted in activation of a 
previously silent, but not tolerant, Th2-1ike population. The 
results of the present experiments directly demonstrate that 
infection with N. brasiliensis can break an established T cell 
tolerance. However, the signals required to induce IL-4 produc- 
tion in normal T ceils, antigen and IL-4, were not capable 
of reversing SEA-specific tolerance in vivo. Furthermore, we 
could demonstrate that the major parameter that correlated 
with the capacity of infection with N,  brasiliensis to break 
tolerance was the magnitude of the lymphoprolfferation seen 
during the course of the infection. Thus, expansion of tolerant 
T 09-41) and B (42) calls appears to be one of the ways in 
which tolerance can be reversed in both T  and B cells. In- 
deed, the polydonal expansion of tolerant T cells seen during 
the course of infectious diseases or treatment with high doses 
of IL-2 may reactivate  tolerized lymphokine pathways  and 
has resulted in the induction of autoimmunity (43). 
Although some studies suggest that the differentiation of 
CD4 + T  cells into Thl- or Th2-1ike subpopulations is es- 
tablished at the time oft cell priming and may become fixed 
in a short period of time (33), we have shown that Thl-like 
T cell clones can still be converted into Th2-1ike cells after 
3 wk of culture (2). Similarly, during the course of an au- 
toimmune disease, autoreactive T ceils are continuously  being 
generated and the administration of IL-4 might influence the 
lymphokine phenotype of these newly produced T cells. In 
this regard, we (Racke,  M. K., A. Bonomo, D. E. Scott, 
B. Cannella, A. D. Levine, C. S. Paine, E. M. Shevach, and 
M. Krcken, manuscript submitted for publication) have re- 
cently shown that the induction of experimental allergic en- 
cephalomyelits by the transfer of Thl-like T  lines can be 
markedly inhibited by the administration of IL-4 at the time 
of cell transfer.  The beneficial effects of the administration 
of IL-4 are associated with the generation of a myelin basic 
protein-specific population of IL-4--producing cells in the 
recipients. 
We thank Drs. W. E. Paul, R. Schwartz, and A. Bonomo for helpful discussion and review of the manu- 
script;  D.  W. Ailing for help with statistics;  and A. D. Levine for the generous supply of IL-4. 
Address correspondence  to Dr. E. M. Shevach,  Cellular Immunology  Section, Laboratory  of Immunology, 
National Institute of Allergy and Infectious Diseases, Building 10, Room 11N315, National Institutes 
of Health, Bethesda, MD 20892. M. Kocken's  present address is Department of Dermatology, Ludwig- 
Maximilians-Universitat Munchen, 8000 Munich 2, Germany. 
Received for publication I4 January  1994 and in revised form  7 March  1994. 
1891  Kocken  et al. R~1'~nce$ 
1.  Mosmann, T.R., J.H. Schumacher, N.F. Street, R. Budd, A. 
O'Garra, T.A.T. Fong, M.W. Bond, K.W.M. Moore, A. Sher, 
and D.F. Fiorentino. 1991. Diversity of  cytokine synthesis and 
function of mouse CD4 § T cells. Iramunol. Rev. 123:209. 
2.  Rocken, M., J-H. Saurat, and C. Hauser. 1992. A common 
precursor for CD4 + T  cells producing  Ib2 or IL-4. f  Im- 
raunol. 148:1031. 
3.  Heinzel, F.P., M.D. Sadick, B.J. Holaday, R.L. Coffman, and 
R..M. Locksley. 1989. Reciprocal expression of interferon 3' 
or interleukin 4 during the resolution or progression of mu- 
fine leishmaniasis. Evidence for expansion of distinct helper 
T cell subsets. J. Ex  F Med. 169:59. 
4.  Murray,  J,S., J. Madri, J. Tite, S.K. Carding, and K. Bottomly. 
1989. MHC control of CD4 + T cell subset activation, f  Ex  F 
Med. 170:2135. 
5.  Pfeiffer,  C., J. Murray, J. Madri, and K. Bottomly. 1991. Selec- 
tive activation of Thl- and Th2-1ike cells in vivo-response 
to human collagen IV. Imraunol. Rev. 123:65. 
6.  Carbailido,  J.M., N. CarbalMo-parrig, G. Terres,  C.H. Heusser, 
and K. Blaser. 1992. Bee venom phospholipase A2-spedfic T 
cell dones from human allergic and non-allergic individuals: 
cytokine patterns change in response to the antigen concen- 
tration.  Fur. J. Iramunol. 22:1357. 
7.  Bretscher, P.A.,  G.  Wei, J.N.  Menon,  and  H.  Bielefeldt- 
Ohmann. 1992. Establishment of stable, cell-mediated immu- 
nity that makes "susceptible"  mice resistant to Leishraania  major. 
Science (Wash. DC). 257:539. 
8.  Rocken, M., K.M. Muller, J-H. Saurat, I. Muller, J.A. Louis, 
J-C.  Cerottini,  and C. Hauser. 1992. Central role for TCK 
/CD3 ligation in the differentiation of CD4 + T cells toward 
a Thl or Th2 functional phenotype, f  Immunol. 148:47. 
9.  Swain, S.L., A.D. Weinberg, M. English, and G. Huston. 1990. 
IL-4 directs the development of Th2-like helper effectors.  J. 
Imraunol. 145:3796. 
10.  Le Gros, G., S.Z. Ben-Sasson, K. Seder, F.D. Finkelman, and 
W.E. paul. 1990. Generation ofinterleukin 4 (II.,4)-producing 
cells in vivo and in vitro: IL-2  and IL-4  are required for in vitro 
generation of Ib4-producing cells. J. Exl~ Med. 172:921. 
11.  Hsieh,  C-S., A.B. Heimberger, J.S.  Gold, A.  O'Garra,  and 
K.M. Murphy. 1992. Differential  regulation ofT helper pheno- 
type development by interleukin  4 and 10 in an oefl T-cell- 
receptor transgenic system. Proa Natl. AcacL Sci. USA. 89:6065. 
12.  Seder, K.A., W.E. paul, M.M. Davis, and B. Fazekas de St. 
Groth. 1992. The presence of interleukin 4 during in vitro 
priming  determines the lymphokine-producing  potential of 
CD4 + T ceils from T cell receptor transgenic mice. J. Exp. 
Med. 176:1091. 
13.  Gajewski, T.F., J. Joyce, and F.W. Fitch. 1989. Antiprolifera- 
tire effect of IFN-3' in immune regulation.  III. Differential 
sdection of T,1 and T,2 murine helper T lymphocyte clones 
using recombinant II.,2 and recombinant IFN-% J. Immunol. 
143:15. 
14.  Finkelman, F.D., I.M. Katona, J.F. Urban, Jr., C.M. Snapper, 
J. Ohara,  and W.E. paul. 1986. Suppression of in vivo poly- 
clonal IgE responses  by monoclonal antibody to the lymphokine 
B-cell stimulatory factor 1. Proa Natl. Acad. Sci, USA. 83:9675. 
15.  Sadick, M.D.,  F.P. Heinzel,  B.J. Holaday, R.T.  Pu,  R.S. 
Dawkins, and IL.M. Locksley.  1990. Cure ofmurine leishman- 
iasis with anti-interleukin 4 monoclonal antibody. Evidence 
for a T cell--dependent,  interferon ~-independent  mechanism. 
J. Exp Med. 171:115. 
16.  Urban,  J.E, Jr.,  K.B. Madden, A.  Svetic, A.  Cheerer,  P.P. 
"I~otta, W.C. Gause, I.M. Katona, and F.D. Finkelman. 1992. 
The importance of Th2 cytokines in protective immunity to 
nematodes. Iraraunol. Rev. 127:205. 
17.  Romani, L., A. Mencacd, U. Grohmann, S. Mocci, P. Mosci, 
P. Puccetti, and F. Bistoni. 1992. Neutralizing antibody to in- 
terleukin  4 induces systemic protection and T  helper type 
1-associated immunity in murine  candidiasis, f  Exp.  Med. 
176:19. 
18.  Schwartz, R.H. 1990. A cell culture model for T lymphocyte 
clonal anergy. Science (Wash. DC).  248:1349. 
19. Jenkins, M.K., and R.H. Schwartz. 1987. Antigen presenta- 
tion by chemically  modified splenocytes  induces antigen-specific 
T  cell unresponsiveness in  vitro and in vivo.  J.  EXl~ Med. 
165:302. 
20.  Gilbert, K.M., K.D. Hoang, and W.O. Wdgle. 1990. Thl and 
Th2 clones differ in their response to a tolerogenic signal J. 
Imraunol. 144:2063. 
21.  Williams, M.E., C.M. Shea, A.H. Lichtman, and A.K. Abbas. 
1992. Antigen receptor-mediated anergy in resting T lympho- 
cytes and T cell clones. Correlation with lymphokine secre- 
tion patterns. J. Iramunol. 149:1921. 
22.  Mueller, D.L., L. Chiodetti, P.A. Bacon, and R.H. Schwartz. 
1991. Clonal anergy blocks the response to IL-4, as well as the 
production of IL-2, in dual-producing T helper cell clones.  J. 
Imraunol. 147:4118. 
23.  Evavold,  B.D., and P.M. Allen. 1991. Separation  of  II.,4 produc- 
tion from Th cell proliferation by an altered T cell receptor 
ligand. Science (Wask. DC). 252:1308. 
24.  Flamand, V., D. Abramowicz, M. Goldman, C. Biernaux, G. 
Huez, J. Urbain, M. Moser, and O. Leo. 1990. Anti-CD3 an- 
tibodies induce T cells from unprimed animals to secrete Ib4 
both in vitro and in vivo. J. Imraunol. 144:2875. 
25.  De Wit, D., M. Van Mechelen, M. Ryelandt, A.C. Figueiredo, 
D. Abramowicz, M. Goldman, H. Bazin, J. Urbain,  and O. 
Leo. 1992. The injection of deaggregated gamma globulins in 
adult mice induces antigen-specific  unresponsiveness  of  T helper 
type 1 but not type 2 lymphocytes. J. Exp Med. 175:9. 
26.  Burstein, H.J., R.I. Tepper, P. Leder, and A.K. Abbas. 1991. 
Humoral immune functions in Ib4 transgenic mice.f Iramunol. 
147:2950. 
27.  Bandeira, A., J. Mengel, O. Burlen-Defranoux, and A. Cou- 
tinho.  1991. Proliferative T  cell anergy to Mls-P does not 
correlate with in vivo tolerance. Int. ImraunoI. 3:923. 
28.  Sprent, J., E-K. Gao, and S.K. Webb. 1990. T cell reactivity 
to MHC molecules: immunity versus tolerance. Science (Wash. 
DC). 248:1357. 
29.  Rocken, M., J.F. Urban,  and E.M. Shevach. 1992. Infection 
breaks T-cell tolerance. Nature (Lond.). 359:79. 
30.  Marrack,  P., and J.  Kappler. 1990. The staphylococcal en- 
terotoxins and their relatives. Science (Wash. DC). 248:705. 
31.  Hu-Li, J., J. Ohara,  C. Watson, W. Tsang, and W.E. Paul. 
1989. Derivation of a T cell line that is highly responsive to 
IL-4 and IL-2 (CT.4R) and of an IL-2 hyporesponsive mutant 
of that line (CT.4S). J. Iraraunol. 142:800. 
32.  Ohara, J., and W.E. Paul. 1985. Production of a monoclonal 
antibody to and molecular characterization of B cell stimula- 
tory factor 1. Nature (Lond.). 315:333. 
33.  Gross, A., S.Z. Ben-Sasson, and W.E. paul. 1993. Anti-IL-4 
diminishes in vivo priming for antigen-specific I1.,4 produc- 
tion by T cells. J. Imraunol. 150:2112. 
1892  Regulation  of the IL-4 Pathway In Vivo 34.  Chatdain, R., K. Varkila, and R.L. Coffman. 1992. IL-4 in- 
duces a Th2 response in Leishmania major-infected mice.J. Im- 
raunol. 148:1182. 
35.  Ben-Sasson, S.Z., G. Le Gros, D.H. Conrad, F.D. Finkelman, 
and W.E. Paul. 1990. IL-4 production by T cells from naive 
donors.  IL-2 is  required  for IL-4 production.  J.  lmmunol. 
145:1127. 
36.  Kundig, T.M., H. Schorle, M.F. Bachmann, H. Hengarmer, 
R.M. Zinkernagel, and I. Horak. 1993. Immune responses in 
interleukin-2-deficient mice. Science (Wash. DC).  262:1059. 
37.  Briner, T.J., M-C. Kuo, K.M. Keating, B.L. Rogers, andJ.L. 
Greenstein. 1993. Peripheral T-cell tolerance induced in naive 
and primed mice by subcutaneous injection of peptides from 
the major cat allergen pel d  I. Proc. Natl.  Acad. Sci. USA. 
90:7608. 
38.  Romball, C.G., and W.O. Weigle. 1993. In vivo induction of 
tolerance in murine CD4 + cell subsets.J. Exl~ Med. 178:1637. 
39.  Andreu-Sanchez,  J.L., I. Moreno de Albor,  tn, M.A.R. Marcos, 
A. S~chez-Movilla,  C. Martinez-A, and G. Kroemer. 1991. 
Interleukin 2 abrogates the nonresponsive state of T cells ex- 
pressing a forbidden T cell receptor repertoire and induces an- 
toimmune disease in neonatally tbymectomized mice. J. Ex  F 
Med. 173:1323. 
40.  Beverly, K, S-M. Kang, M.J. Lenardo, and R..H. Schwartz. 
1992. Keversal  of  in vitro T cell clonal anergy by IL-2 stimula- 
tion. Int. lmmunoI.  4:661. 
41.  Heath, W.K., J. Allison, M.W. Hoffmann, G. Schonrich, G. 
Hammerling,  B. Arnold, and J.F.A.P. Miller. 1992. Autoim- 
mune diabetes as a consequence of locally produced  inter- 
leukin-2. Nature (Lond.). 359:547. 
42.  Goodnow, C.C., K. Brink, and E. Adams. 1991. Breakdown 
of self-tolerance in  anergic B lymphocytes. Nature  (Lond.). 
352:532. 
43.  Rocken, M., and E.M. Shevach. 1993. Do parasitic infections 
break T-cell  tolerance  and trigger autoiramune disease?  Parasitol. 
~day.  9:377. 
1893  P,  ocken et al. 